Tenderwize
Zurück zur Suche

Open House Originale Agreement for Ponesimod

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 429 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-26 - Ponesimod

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Offers/contracts cannot be submitted through the procurement portal; they must be sent by email with qualified electron...

Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal product and requires the stated AMG...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply arrangement for pharmaceutical products concerning the active substance Ponesimod.
  • Open House original rebate contracts under Section 130c(1) SGB V.
Vollständige Zusammenfassung anzeigen

This is a German Open House supply arrangement for pharmaceutical products, specifically Ponesimod, led by Techniker Krankenkasse with participating sickness funds. It is not a classic competitive award procedure: all suitable pharmaceutical companies meeting the stated conditions may join during the contract period. No estimated contract value is provided. The contract runs from 01.11.2025 to 31.10.2027 at the latest, with automatic earlier end if patent/market exclusivity expires. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the participation documents are only available electronically on the portal.

Risiken

Offers/contracts cannot be submitted through the procurement portal; they must be sent by email with qualified electron...

Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal product and requires the stated AMG...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale Agreement for Ponesimod

Single lot for an Open House original rebate agreement for the active substance Ponesimod. Scope is nationwide in Germany. The arrangement is open to all suitable pharmaceutical companies that meet the stated legal and self-declaration requirements. No exclusivity and no individual negotiation apply. The lot information comes from structured data and the notice text.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Frist

Deadline Oct 30, 2027

Vergabedetails

Veröffentlichungsdatum
08 Sep 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
586433-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3